Authors
Amparo Olivares, Ana María Mercado, Daniel Gyingiri Achel, José Antonio García-Gamuz, Julián Castillo, Miguel Alcaraz
Published in
International journal of radiation biology. Pages 1-12. Aug 26, 2026. Epub Aug 26, 2026.
Abstract
Four cell lines with differing degrees of radiosensitivity were employed: PNT2 (non-tumoral prostate epithelial cells used as reference), MELAN A (normal murine melanocytes), SK-MEL-1 (human metastatic melanoma cells), and B16F10 (murine metastatic melanoma cells). Cell survival assays, apoptosis, intracellular glutathione status, and cell cycle progression were evaluated 48 hours following exposure to 20 Gy X-rays, with or without RA pretreatment at 25 µM administered 15 minutes before irradiation.
In PNT2 cells, RA conferred robust radioprotection with a protection factor of 99 ± 1.0% (p < .001), reducing radiation-induced apoptosis by more than 300%, significantly increasing the GSH/GSSG ratio, and normalizing cell cycle distribution. In MELAN-A and SK-MEL-1 cells, RA abolished radioprotection, reduced the GSH/GSSG ratio, and increased the apoptotic fraction. In B16F10 cells, RA tripled radiation-induced cell death (p < .001), further depleted the GSH/GSSG ratio, increased apoptosis, and markedly aggravated G2/M arrest, demonstrating a frank and significant radiosensitizing effect. The loss of radioprotective capacity is: B16F10 > Melan-A = SK-MEL-1 > PNT2 (p < .001).
RA exhibits a cell-type-dependent radiomodulatory profile: it effectively protects normal epithelial cells while losing its radioprotective capacity-or acting as a radiosensitizer-in melanin-producing cells. Confirmation of this selectivity in vivo studies could represent a promising strategy to widen the therapeutic window in melanoma radiotherapy.
PMID:
42644732
Bibliographic data and abstract were imported from PubMed on 26 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 10
- Comments 0